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Abstract
Introduction Induction of an inflammatory response is thought
to have a significant role in the complications that follow
cardiopulmonary bypass (CPB). The statin drugs are
increasingly being recognized as having potent anti-
inflammatory effects and hence have potential to influence an
important mechanism of injury in CPB, although there is no
current confirmation that this is indeed the case. Our objective
was to systematically review if pre-operative prophylactic statin
therapy, compared with placebo or standard of care, can
decrease the inflammatory response in people undergoing heart
surgery with CPB.
Methods We performed a systematic and comprehensive
literature search for all randomized controlled trials (RCTs) of
open heart surgery with CPB in adults or children who received
prophylactic statin treatment prior to CPB, with reported
outcomes which included markers of inflammation. Two authors
independently identified eligible studies, extracted data, and
assessed study quality using standardized instruments.
Weighted mean difference (WMD) was the primary summary
statistic with data pooled using a random effects model.
Descriptive analysis was used when data could not be pooled.
Results Eight RCTs were included in the review, with the
number of trials for each inflammatory outcome being even more
limited. Pooled data demonstrated benefit with the use of statin
to attenuate the post-CPB increase in interleukins 6 and 8 (IL-6,
IL-8), peak high sensitivity C-reactive protein (hsCRP), and
tumor necrosis factor-alpha (TNF-α) post-CPB (WMD [95%
confidence interval (CI)] -23.5 pg/ml [-36.6 to -10.5]; -23.4 pg/
ml [-35.8 to -11.0]; -15.3 mg/L [CI -26.9 to -3.7]; -2.10 pg/ml [-
3.83 to -0.37] respectively). Very limited RCT evidence
suggests that prophylactic statin therapy may also decrease
adhesion molecules following CPB including neutrophil CD11b
and soluble P (sP)-selectin.
Conclusions Although the RCT evidence may suggest a
reduction in post-CPB inflammation by statin therapy, the
evidence is not definitive due to significant limitations. Several of
the trials were not methodologically rigorous and statin
intervention was highly variable in this small number of studies.
This systematic review demonstrates that there is a significant
gap that exists in the current literature in regards to the potential
anti-inflammatory effect of statin therapy prior to CPB.
Introduction
The use of cardiopulmonary bypass (CPB) is necessary for
many cardiac surgical procedures. However, it is clear that
CPB can have deleterious effects, including initiation of cardi-
opulmonary dysfunction, renal dysfunction, and neurological
injury in the acute peri-operative period. Economic costs and
the human costs are greater when cardiac surgical patients
develop complications following CPB [1,2]. A number of dif-
ferent prophylactic strategies have been employed in attempts
to improve clinical outcomes following CPB [3]. Previous sys-
tematic reviews and meta-analysis have looked at the effects
of some of these interventions for preventing post-CPB organ
dysfunction and there is no definitive evidence that these inter-
ventions are beneficial [4-6]. Thus, the development and use
CABG: coronary artery bypass graft; CENTRAL: The Cochrane Central Register of Controlled Trials; CI: confidence interval; CPB: cardiopulmonary 
bypass; hsCRP: high sensitivity C-reactive protein; ICAM-1: intercellular adhesion molecule-1; IL: interleukin; NNT: number needed to treat; RCT: 
randomized controlled trials; RD: risk difference; RR: risk ratio; sP-selectin: soluble P-selectin; TNF-α: tumor necrosis factor-alpha; WMD: weighted 
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of new strategies aimed at reducing post-operative morbidity
and mortality following CPB is of importance.
It is well documented that CPB is associated with a systemic
inflammatory response, which involves the synthesis of various
cytokines and inflammatory mediators [7]. This inflammation
sets the stage for initiation of injury of major organs (including
multiple organ dysfunction syndrome) as well as amplification
of injury induced by alterations in vasoreactivity and organ per-
fusion [8]. Statins are being increasingly recognized as having
pleotrophic (non-lipid mediated) effects, including inhibition of
inflammation [9]. Given that statins can exert direct anti-inflam-
matory effects and what is understood about organ injury post-
CPB, it is tempting to speculate that these drugs might have
broad potential as an intervention in the pre-operative care of
people undergoing CPB.
Previous reviews and meta-analyses that have looked at the
clinical impact of pre-operative statin treatment on major
adverse events after cardiovascular surgery have suggested a
beneficial impact. For example, a systematic review by Liako-
poulos and colleagues [10], which included 3 randomized
controlled trials (RCTs), and 16 observational studies (3 pro-
spective and 13 retrospective), reported outcomes of 31,725
cardiac surgery patients with or without pre-operative statin
therapy. The meta-analysis provided evidence that pre-opera-
tive statin therapy exerts substantial clinical benefit on early
post-operative adverse outcomes in cardiac surgery patients
(including mortality, atrial fibrillation and stroke). A previous
systematic review by Hindler and colleagues [11] had demon-
strated a variable effect of peri-operative statin on post-opera-
tive cardiovascular morbidity. Given the limitations of the
evidence base for these systematic reviews, the need for fur-
ther RCTs was underscored by the investigators, with the
empirical use of statins for all patients undergoing cardiac sur-
gery not supported.
Understanding the biological mechanism by which statins may
change the clinical course following cardiac surgery with CPB
is important as we move forward in the development of large
high-quality RCTs to further address the clinical efficacy of this
intervention. It has not been demonstrated by systematic
review that statins can modify the biological processes that
are related to organ injury post-CPB. It is therefore prudent to
systematically review this existing literature. The primary objec-
tive of this review was to answer the following question: in
people undergoing heart surgery with CPB, does pre-opera-
tive prophylactic statin therapy, compared with placebo or
standard of care, decrease the inflammatory response after
CPB?
Materials and methods
This systematic review was conducted and reported in
accordance with available guidelines [12].
Criteria for considering studies for this review
Criteria for types of studies were as follows: randomized clini-
cal trials, with or without placebo. Studies were eligible if they
included male or female patients of any age undergoing CPB
for elective open-heart surgery (open-heart surgery could
include surgery for coronary artery bypass, valve repair, or con-
genital heart lesions). Studies of patients undergoing heart
transplant were excluded. Patients already on statins were
excluded. Criterion for type of intervention was the pre-opera-
tive use of any statin drug administered as prophylaxis pre-
CPB, with or without other interventions, compared with a
non-statin containing control regimen (either standard of care
or placebo). Co-interventions were allowed as long as all arms
of the randomized allocation received the same co-interven-
tions. The primary evaluation criterion for outcomes measures
was the measurement of inflammatory markers post-opera-
tively (e.g. interleukins (IL-6, IL-8, IL-1), TNF-α and its recep-
tors, high sensitivity C-reactive protein (hsCRP), adhesion
molecules (neutrophil CD11b, intercellular adhesion mole-
cule-1 (ICAM-1), selectins), complement split products (C3a,
C5a)).
Search methods for identification of studies
We conducted a comprehensive search to identify all relevant
studies of statin use. Cochrane Central Register of Controlled
Trials (CENTRAL), MEDLINE (1950 to March 2009),
EMBASE (1988 to March 2009), and International Pharma-
ceutical Abstracts (1970 to March 2009) were searched
using relevant search terms relating to heart surgery proce-
dures with CPB and statins [see Additional data file 1 for
details of search strategies]. PubMed was searched for in-
process records and other non-indexed citations. A number of
clinical trials registers (n = 4) and a variety of meeting abstract
(n = 5) and grey literature (Grey Literature Report) sources
were searched. The citations of existing reviews and trials
identified were reviewed to identify pertinent studies and arti-
cles citing the retrieved trials were identified by PubMed and
via Web of Science.
For knowledge of ongoing or unpublished trials, we contacted
investigators of all identified trials, a number of groups identi-
fied through the United States National Library of Medicine's
Directory of Health Organizations and the Cochrane Collabo-
rative Review Groups' Specialized Register, and pharmaceuti-
cal companies. Studies in all languages were included.
Data collection and analysis
Selection of trials
Two authors (CM and either MZ or PG) independently
assessed titles and abstracts identified from the electronic
database searches, applying predetermined eligibility criteria.
If two reviewers were certain that a reference was not relevant
it was excluded. Disagreements between authors were solved
by consensus. Full text of articles that were judged to be
potentially eligible by title and abstract review as above wereAvailable online http://ccforum.com/content/13/5/R165
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retrieved and two reviewers (CM and MZ) assessed them for
eligibility using the inclusion and exclusion criteria. If both were
certain that a study was unsuitable it was excluded and rea-
sons for exclusion noted. Disagreements between authors
were solved by consensus. The reviewers were not blinded for
authors' names or journal names. The numbers of references
retrieved from the searches was recorded. Those eligible or
ineligible were documented and a quality of reporting of meta-
analysis (QUOROM) statement prepared [12] (Figure 1).
Assessment of methodological quality of included studies
Quality of the studies was assessed by two reviewers (CM
and either MZ or PG) without blinding to the journal or author-
ship, using the established standards of the Cochrane Collab-
oration (Cochrane collaboration Risk of Bias Assessment
Tool) [13]. The quality items assessed were sequence gener-
ation, allocation concealment, blinding of participants, person-
nel and outcome assessors, completeness of outcome data,
selective outcome reporting, and other sources of bias. Each
item was assessed as adequate (i.e. low risk of bias), inade-
quate (high risk of bias), or unclear (uncertain risk of bias). For
detailed description of this tool for assessing risk of bias see
Table 8.5a in the Cochrane Handbook [13]. The methodolog-
ical quality of the selected studies was scored overall by a
summary assessment of the risk of bias; low, unclear, and high
risk were the three possible categories. Studies judged as low
risk of bias scored as adequate for all key items. Studies
judged as unclear risk of bias scored as unclear for one or
more key items. Studies judged as high risk of bias scored as
inadequate for one or more key items. If information was not
available in the trial reports necessary for risk of bias assess-
ment, further information was sought by correspondence with
the principal investigator(s). Discrepancies between reviewers
were resolved by discussion.
Data extraction for articles meeting the inclusion criteria
Data was extracted independently by two reviewers (CM and
MZ) and was collected on a data extraction form, which had
been pre-tested to ensure appropriate data collection. This
form included basic identifying information, information on trial
quality, and information on trial participants, interventions, and
outcomes related to post-operative inflammatory markers.
Data regarding the clinical endpoints of mortality and morbidity
was also extracted.
Statistical methods
Data were analyzed using Review Manager (RevMan) 5 for
analysis. For continuous variables (e.g. levels of inflammatory
markers) weighted mean difference (WMD) with 95% confi-
dence interval (CI) was used when combining data. Data was
pooled where appropriate using random effects models and
statistical heterogeneity was quantified using the I2 statistic
[14].
Figure 1
Flowchart for selection of randomized control trials Flowchart for selection of randomized control trials.  RCT = randomized controlled trial.Critical Care    Vol 13 No 5    Morgan et al.
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Results
Description of studies
Of the 2322 titles and abstracts found, 17 studies were iden-
tified as potentially suitable and the full text retrieved (Figure
1). Fifteen of these studies were English language; the other
two studies (one Chinese and one Spanish with the abstracts
in English) were translated to allow classification and further
analysis. Of the 17 studies, we included 8 studies in the review
and excluded 9 studies. One of the nine excluded studies is
eligible for inclusion (Nakamura and colleagues [15]); how-
ever, only a subgroup of the study sample had CPB and this
data is not available in published form (we have attempted to
contact the author with no response and hence have not
included it further in the review). Four excluded studies did not
fulfill the methodological criteria because they were non-rand-
omized, prospective cohort studies [16-19]. Four studies were
excluded due to type of outcome measures [20-23]. A break-
down of each of the excluded studies, as well as the study by
Nakamura and colleagues [15], addressing the specifics of
their study design and outcomes can be found in Additional
data file 2: characteristics of excluded studies, studies await-
ing assessment, and ongoing studies. We obtained all of the
included studies as a result of the database searches. With
the exception of Tamayo and colleagues [24], we have had
limited success in receiving adequate information and feed-
back from the authors that we have attempted to contact, in
spite of repeated attempts. Details of included studies are
given in Table 1. We identified two ongoing RCTs fulfilling eli-
gibility criteria. One was identified through the Australian New
Zealand Clinical Trials Registry with registration number
ACTRN12606000405516 [25] and the other was through
ClinicalTrials.gov, a service of the U.S. National Institutes of
Health, with registration number NCT00791648 [26]. Details
are given in Additional data file 2: characteristics of excluded
studies, studies awaiting assessment, and ongoing studies. All
of the included and excluded studies were published between
2001 and 2009.
The eight included studies comprised a total of 638 patients;
312 of these received prophylactic statin treatment prior to
CPB and 296 acted as controls. The 2007 study by Chello
and colleagues [27] has three study arms; one group received
statin pre-operatively before CPB, one group received a pla-
cebo before CPB and a third group served as a control group
undergoing surgical intervention but not CPB. We have
excluded the third arm of the study. A total of 15 patients were
excluded from the review due to this process. We were then
left with a total of 623 patients, 312 of whom received statin
treatment and 311 who acted as controls. All selected studies
involved adult populations. Out of 312 patients receiving stat-
ins, 238 were male and 225 out of 311 patients acting as con-
trols were male. Six trials were performed in patients
undergoing coronary artery bypass graft (CABG) surgery
[24,27-31] and two trials [32,33] were performed in patients
undergoing various cardiac operations that required CPB
(CABG, valve replacements and aortic aneurysm repair).
Various statin treatments were used in the different trials. Two
trials used simvastatin: one trial used 40 mg/day [27] and the
other used 20 mg/day [24]. Three trials used atorvastatin: one
trial used 40 mg/day [32], one trial used 20 mg/day [30], and
one trial used 40 mg twice per day [33]. Rosuvastatin was
used in one trial at a dose of 20 mg/day [31]. Fluvastatin was
used in one trial at a dose of 80 mg/day [28]. Pravastatin was
used in one trial at a dose of 40 mg/day [29]. The duration of
administration prior to CPB also varied between trials. Four tri-
als administered treatment for three weeks before surgery
[24,27,28,30], two trials administered treatment for one week
before surgery [31,32], one trial administered treatment for
two days before surgery [29], and one trial administered treat-
ment one day before surgery [33].
Risk of bias in included studies
Overall, study quality was not high, with only two studies hav-
ing low risk of bias [31,32], four studies having unclear risk of
bias [24,27,28,30], and two studies with high risk of bias
[29,33] (Figure 2). All of the trials, with the exception of two,
were small [31,32]. Three studies [28,30,32] discussed sam-
ple size determination or whether the study was adequately
powered to demonstrate significance, in relation to the primary
outcomes of interest for this systematic review. Authors were
contacted for further methodological detail, but no additional
information was provided. The authors of two studies explicitly
stated no disclosures [30,32]. None of the publications men-
tioned any conflict of interest with respect to the drugs used
and hence we assumed that none existed.
Effects of interventions
With the exception of CD11b and hsCRP in one study [31],
no studies reported change scores before and after CPB,
although all studies measured pre-operative and post-opera-
tive levels of inflammatory markers. All of the studies in the
review demonstrated no difference between groups for base-
line measure of inflammatory markers prior to CPB. The only
outcome demonstrating heterogeneity in pooled analysis by I2
statistic was hsCRP; I2 = 0 for all other pooled outcomes.
IL-6
Five of the included studies with 175 participants reported
post-operative IL-6 level [24,27,29,30,33]. All five RCTs spec-
ified IL-6 as a primary outcome. The type of statin used varied
(atorvastatin in two trials, simvastatin in two trials and pravas-
tatin in one trial) and duration of pre-operative therapy ranged
from 18 hours to 3 weeks. Only four of these studies were
pooled, because we were unclear if the report by Florens and
colleagues [33] provided the necessary data to be included in
the pooled comparison; we suspect the data is skewed and it
is unclear how the data is represented.Available online http://ccforum.com/content/13/5/R165
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Table 1
Characteristics of included studies
Trial Methods Participants Interventions Outcomes
Berkan et al. [28] Randomized but method 
not clear; unclear allocation 
concealment but adequate 
blinding; unclear risk of 
bias.
CABG with CPB. Statin 
group n = 23, age, mean = 
65.4, SD 11.2; control 
group n = 23, age, mean 
67.7, SD 9.6.
Statin group duration of 
CPB, mean 122.4, SD 
36.9; control group 
duration of CPB, mean 
113, SD 27.2.
Fluvastatin 80 mg daily for 
3 weeks before CPB. 
Control group received 
placebo in same manner.
sP-selectin level; clinical 
outcomes (inotrope use, 
length of ICU and hospital 
stay, incidence of MI).
Caorsi et al. [29] Randomized but method 
not clear; unclear allocation 
concealment and not 
blinded; high risk of bias.
CABG with CPB. Statin 
group n = 21, age, mean = 
68.2, SD 7.2; control group 
n = 22, age, mean 67.9, SD 
7.3.
Statin group duration of 
CPB, mean 93.8, SD 9.1; 
control group duration of 
CPB, mean 94.1, SD 7.7.
40 mg pravastatin daily 
from 48 hours prior to CPB 
to post-operative day 7; 
additional dose 1 hour 
after CPB. Control group 
received standard of care 
with no placebo. Both 
groups received aspirin 6 
hours after CPB.
Inflammatory cytokines
Chello et al. (2006) [30] Randomized but method 
not clear; unclear allocation 
concealment but adequate 
blinding; unclear risk of 
bias. a
CABG with CPB. Statin 
group n = 15, age, mean = 
65.7, SD 7.7; control group 
n = 15, age, mean 63.7, SD 
7.1.
Statin group duration of 
CPB, mean 97, SD 5.5; 
control group duration of 
CPB, mean 94.3, SD 8.6.
Atorvastatin 20 mg daily for 
3 weeks before CPB. 
Control group received 
placebo in same manner.
Inflammatory cytokines; 
neutrophil adhesion and 
function; endothelial nitric 
oxide release; SIRS
Chello et al. (2007) [27] Randomized but method 
not clear; unclear allocation 
concealment but adequate 
blinding; unclear risk of 
bias.
CABG with CPB. Statin 
group n = 15, age, mean = 
67.7, SD 6.2; control group 
n = 15, age, mean 66.3, SD 
7.5.
Statin group duration of 
CPB, mean 97.9 SD 19.4; 
control group duration of 
CPB, mean 102.5, SD 
28.2.
Simvastatin 40 mg daily 
starting 3 weeks prior to 
CPB. Control group 
received placebo in same 
manner.
Inflammatory cytokines; 
neutrophils apoptosis and 
function.
Florens et al. [33] Randomized but method 
not clear; unclear allocation 
concealment; not blinded; 
some patients received 
aprotinin, although 
indications not given; high 
risk of bias. b
Heart surgery with CPB. 
Statin group n = 10, age, 
mean = 68, SD 18; control 
group n = 10, age, mean 
62, SD 12. Statin group 
duration of CPB, mean 89, 
SD 24; control group 
duration of CPB, mean 93, 
SD 35.
Atorvastatin 40 mg 18 hrs 
pre-operatively and 40 mg 
immediately pre-
operatively. Control group 
received standard of care 
with no placebo.
Inflammatory 
cytokines;atrial biopsy for 
nuclear factor kappa B; 
clinical outcomes 
(ventilation time, fever, 
leukocytosis, renal 
dysfunction, MI, inotrope 
use)
Mannacio et al. [31] Randomized; allocation 
concealed and adequate 
blinding; low risk of bias.
CABG with CPB. Statin 
group n = 100, age, mean 
61.3, SD 9.2; control group 
n = 100, age, mean 59.3, 
SD 8.4.
Statin group duration of 
CPB, mean 80.6, SD 22.4; 
control group duration of 
CPB, mean 83.8, SD 25.2
Rosuvastatin 20 mg daily 
starting 7 days before 
CPB; Control group 
received placebo in same 
manner.
hsCRP; myocardial 
damage; atrial fibrillation; 
low output syndrome; renal 
failureCritical Care    Vol 13 No 5    Morgan et al.
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The pooled data (Figure 3), which equates to a total of 155
participants, demonstrated benefit with the use of statin to
reduce the post-operative peak level of IL-6 (WMD -23.5 pg/
ml, 95% CI -36.6 to -10.5) measured at four to six hours post-
CPB. Three of the pooled studies were of unclear risk of bias
and one was high risk of bias [29].
Although the study by Florens and colleagues [33] reports that
they failed to demonstrate this benefit, graphic representation
of the data shows a point estimate of the four hour post-CPB
IL-6 level in the statin group that is 25% of the four hour post-
CPB IL-6 level in the control group.
IL-8
Three of the included studies with 80 participants reported
post-operative IL-8 level [27,30,33]. All three RCTs specified
IL-8 as a primary outcome. Two trials used atorvastatin and
one trial used simvastatin. Duration of pre-operative therapy
ranged from 18 hours to 3 weeks. Again, only two of the stud-
ies were pooled because we were unclear of the distribution
and data reporting in the study by Florens and colleagues [33].
Both of the studies pooled came from the same investigative
group and were both judged to be of unclear risk of bias. The
pooled data (Figure 4) demonstrated benefit with the use of
statin to reduce the post-operative level of IL-8 (WMD -23.4
pg/ml, 95% CI -35.8 to -11.0), measured four hours post-
CPB. Florens and colleagues [33], which was judged to be of
high risk of bias, reported failure to demonstrate this benefit,
although the point estimate of the four-hour post-CPB IL-8
level in the statin group is lower than the four-hour post-CPB
IL-8 level in the control group estimate for post bypass level.
hsCRP
Four studies with 487 participants reported post-operative
hsCRP [24,29,31,32]. Two RCTs specified hsCRP as a pri-
mary outcome [24,29]. Each trial used a different statin (prav-
astatin, simvastatin, rosuvastatin, atorvastatin). Duration of pre-
operative therapy ranged from 48 hours to 3 weeks. Two stud-
ies were low risk of bias, one study was unclear risk of bias,
and one study was high risk of bias. The pooled analysis (Fig-
ure 5) demonstrated benefit with the use of statin to reduce
the post-operative peak level of hsCRP (WMD -15.3 mg/L,
95% CI -26.9 to -3.7). Each trial measured hsCRP at 24-hour
intervals post-CPB to a minimum of 48 hours and reported
'peak' levels; however, only two trials [24,29] specified the
time at which this peak occurred (48 hours post-CPB). The
percent of variance due to between-study variance was mod-
erate to substantial (I2 = 55%). The two individual studies
judged to be low risk of bias and with significantly larger
number of participants in each (n = 200) show discrepant
results. Patti and colleagues [32] demonstrated that peak
hsCRP levels after the operation did not differ between treat-
ment and control groups (164 ± 37 versus 166 ± 51 mg/L, P
= 0.75). In Mannacio and colleagues [31], mean post-opera-
tive peak hsCRP level was significantly lower in the treatment
group compared with the control group (154 ± 2.5 mg/L ver-
sus 172 ± 3.4 mg/L, P < 0.001). Neither of these studies
specified at which time point peak hsCRP was measured. The
duration of pre-operative statin therapy was the same in both
Patti et al. [32] Randomized; allocation 
concealed and adequate 
blinding; low risk of bias.
Heart surgery with CPB 
(CABG, valve repair, aortic 
aneurysm repair). Statin 
group n = 101, age, mean 
65.5, SD 8.8; control group 
n = 99, age, mean 67.3, SD 
8.1. Statin group duration 
of CPB, mean 113, SD 37; 
control group duration of 
CPB, mean 105, SD 30.
Atorvastatin 40 mg daily for 
7 days before CPB; 
continued day after surgery 
until discharge. Control 
group received placebo in 
same manner.
Post-operative atrial 
fibrillation; length of post-
operative hospital stay; 
major cardiac/
cerebrovascular adverse 
events; hsCRP levels.
Tamayo et al. [24] Randomized but method 
not clear; unclear allocation 
concealment; state that 
except for perfusionist, no 
member of medical team 
knew what group patient 
was randomized to; 
however there was no 
placebo given. Blinding of 
investigators is unclear. c
CABG with CPB. Statin 
group n = 22, age, mean 
67.7, SD 7.3; control group 
n = 22, age, mean 68, SD 
6.9. Statin group duration 
of CPB, mean 106.8, SD 
26.9; control group 
duration of CPB, mean 
96.2, SD 24.6.
Simvastatin 20 mg/day for 
3 weeks before surgery 
versus no pre-operative 
simvastatin treatment.
hsCRP; IL-6; C4; clinical 
outcomes (renal 
dysfunction, ventilation).
CABG = coronary artery bypass graft; CPB = cardiopulmonary bypass; C4 = complement component 4; hsCRP = high sensitivity C-reactive 
protein; ICU = intensive care unit; IL-6 = interleukin-6; MI = myocardial infarction; SD = standard deviation; SIRS = systemic inflammatory 
response score; sP-selectin = soluble P-selectin
a No response to letter requesting details.
b Statistical tests requiring the assumption of normal distribution were used to detect between-group differences in cytokine levels (despite small 
sample size and no confirmation that data was indeed normally distributed, graphical representation suggests that data is likely skewed).
c Data in the original paper is presented in graphical form. The author was contacted and provided exact point estimates and variability of the data 
which was not included in the published form.
Table 1 (Continued)
Characteristics of included studiesAvailable online http://ccforum.com/content/13/5/R165
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studies (1 week), although they differed in terms of the statin
used (rosuvastatin [31] and atorvastatin [32]). Participants in
both studies were predominantly undergoing CABG; how-
ever, Mannacio and colleagues [31] excluded patients under-
going additional cardiac surgery while Patti and colleagues
[32] included a population having valve repair. Mean time on
CPB was longer in the trial by Patti and colleagues [32].
TNF-α
Three of the included studies with 103 participants measured
post-operative TNF-α level [27,29,30]. All three RCTs speci-
fied IL-8 as a primary outcome. One trial used atorvastatin, one
trial used simvastatin, and one trial used pravastatin. Duration
of pre-operative therapy ranged from 48 hours to 3 weeks.
Caorsi and colleagues [29] present no data on the TNF-α
level; they state that both groups showed low levels through-
out the entire study; however, the detection limit of their tech-
nique was 10 pg/ml which is significantly higher than the
detection limit in other included studies. The pooled data of
two studies [27,29,30] (70 participants), demonstrated bene-
fit with the use of statin to reduce the post-operative level of
TNF-α (WMD -2.10 pg/ml, 95% CI -3.8 to -0.4) (Figure 6).
Both of the studies pooled came from the same investigative
group and were both judged to be of unclear risk of bias.
Adhesion molecules
CD11b
Three of the included studies with 80 participants reported
neutrophil CD11b expression [27,30,33]. Two trials used
atorvastatin and one trial used simvastatin. Duration of pre-
operative therapy ranged from 18 hours to 3 weeks. All three
studies specified CD11b expression as a primary outcome.
Florens and colleagues [33] measured CD11b expression by
neutrophils isolated from blood drawn at the beginning and
end of CPB. They report that post-CPB values of expression
were significantly higher than pre-CPB expression and that
Figure 2
Methodological quality summary Methodological quality summary.  Review authors' judgements about 
each methodological quality item for each included study; light grey cir-
cle/(+) indicates adequate; dark grey circle (-) indicates inadequate; 
blank box indicates unclear.
Figure 3
Forest plot of comparison for prophylactic statin therapy versus standard care/placebo: Inflammatory markers, outcome: IL-6 Forest plot of comparison for prophylactic statin therapy versus standard care/placebo: Inflammatory markers, outcome: IL-6.  Total refers to number 
of patients per trial. CI = confidence interval; SD = standard deviation.Critical Care    Vol 13 No 5    Morgan et al.
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statin had no effect on this change from baseline, although no
statistical analysis for this is published.
The 2006 study by Chello and colleagues [30] also measured
CD11b expression in neutrophils isolated from blood drawn at
0 (at CPB termination), 4 and 12 hours post-CPB; statin treat-
ment significantly decreased the percent increase in CD11b
expression relative to baseline at 4 and 12 hours (mean differ-
ence of -63%, 95% CI -92% to -34% at 4 hours and mean dif-
ference of -47%, 95% CI -71 to -22 at 24 hours).
The 2007 study by Chello and colleagues [27] measured
expression by neutrophils isolated from blood drawn at the
end of bypass and cultured for 8, 12, and 24 hours and report
that CD11b expression was significantly higher (P < 0.01) in
samples from the placebo group (145% increase in expres-
sion) compared with the statin group (102% increase in
expression) after 24 hours of culturing.
ICAM-1
One of the studies, judged as high risk of bias, reported the
effect of statin on the soluble form of the endothelial ICAM-1
[33]. The level measured 24 hours post bypass did not differ
between statin and control groups (294 ± 70 versus 258 ± 94
ng/ml, P = 0.34)
P-selectin
Two studies describe measuring P-selectin levels following
CPB [28,33], Florens and colleagues [33] report that post-
operative values were not different between statin (n = 10)
and control (n = 10) groups for any of the tested markers but
do not provide data. This study was judged as high risk of bias.
In the study by Berkan and colleagues [28], peak P-selectin
levels were significantly different between statin (n = 23) and
control (n = 23) (164.77 ± 15.5 ng/ml versus 260 ± 9.98 ng/
ml, P < 0.001)). This study was judged as unclear risk of bias.
Discussion
Statins are beginning to be used in a number of clinical situa-
tions where inflammation is considered a major pathophysio-
logical mechanism including in people undergoing CPB.
Pooled data in this systematic review demonstrates that statin
therapy before CPB is associated with a reduction in circulat-
ing markers of inflammation, specifically IL-6, IL-8, hsCRP, and
TNF-α. For IL-6 and IL-8, one additional trial, which was not
pooled due to limitations of the original data, illustrates a 75%
reduction in IL-6 with statin given pre-CPB and a 20% reduc-
tion in IL-8 with statin given pre-CPB. These reductions in
inflammatory markers were not reported as significant in the
original article; however, the sample size was very small. For
TNF-α, un-pooled data which represents one additional study
suggests that both treatment and control groups had similar
levels of TNF-α throughout the study, although they were all
Figure 4
Forest plot of comparison for prophylactic statin therapy versus standard care/placebo: Inflammatory markers, outcome: IL-8 Forest plot of comparison for prophylactic statin therapy versus standard care/placebo: Inflammatory markers, outcome: IL-8.  Total refers to no. of 
patients per trial. CI = confidence interval; SD = standard deviation.
Figure 5
Forest plot of comparison for prophylactic statin therapy versus standard care/placebo: Inflammatory markers, outcome: hsCRP Forest plot of comparison for prophylactic statin therapy versus standard care/placebo: Inflammatory markers, outcome: hsCRP.  Total refers to no. 
of patients per trial. CI = confidence interval; SD = standard deviation.Available online http://ccforum.com/content/13/5/R165
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below the detection limit for their assay. In addition, the detec-
tion limit of the assay used was not adequate, given the mean
for TNF-α concentrations in other studies included in the
review.
For IL-8 and TNF-α, pooled analysis was limited to only two
studies, both of which came from the same investigative group
[27,30]; no heterogeneity was detected between these two
studies in pooling for either of these outcomes, which is not
surprising given similar trial characteristics. It is of interest that
the type of statin used was different between these trials (ator-
vastatin [30] and simvastatin [27]), which might suggest drug
type is not an important determinant of between study differ-
ences. For IL-6, although our conclusions from pooled analysis
are based on only four RCTs with different drug interventions,
they are somewhat strengthened by the homogeneity of study
results. Although pooled analysis detected a benefit of treat-
ment with statin for reducing peak hsCRP level, there was
moderate to substantial heterogeneity. Given the small
number of included trials, subgroup/sensitivity analysis could
not investigate potential between study differences. In addi-
tion, the two high-quality studies with larger number of partici-
pants demonstrated differing results, the reason for which is
not clear.
Prophylactic statin therapy may decrease adhesion molecules
following CPB including neutrophil CD11b and soluble P (sP)-
selectin, although the evidence for this is weak. Neutrophil
CD11b surface adhesion molecule expression is a marker of
neutrophil stimulation. Although statin does not appear to
change expression immediately following CPB, other data
supports an effect of statin on neutrophils when assessed
after a period of time more appropriate for protein transcription
to occur.
Seven of the eight studies identified for inclusion in this sys-
tematic review measured clinical outcomes [24,28-33]. For
the majority of the studies, clinical endpoints were not identi-
fied as primary outcomes. Given the small number of partici-
pants in these studies, the rarity of the events, and the limited
numbers of trials to include in meta-analysis, we have not
reported detailed results for these outcomes. In light of the fact
that we did not systematically search for these outcomes, lim-
ited conclusions can be made. Previous systematic reviews
have shown the beneficial effect of pre-operative statin treat-
ment on major adverse cardiac outcomes including atrial fibril-
lation [10,11]. Four of the studies included in this review
measured risk of atrial fibrillation [29-32] (483 participants,
event rate 34%) and pooled analysis demonstrated benefit
with the use of pre-operative statin to reduce atrial fibrillation
post-operatively (risk ratio (RR) 0.58, 95% CI 0.45 to 0.75,
risk difference (RD) -0.19, 95% CI -0.27 to -0.10, number
needed to treat (NNT) 5, 95% CI 4 to 10). Statins also
appeared to decrease the risk of inotrope use (4 studies
[28,30-32], 486 participants, event rate 23%, RD -0.08, 95%
CI -0.21 to -0.04, NNT 12, 95% CI 5 to 25).
Overall this review suggests that several markers of the inflam-
matory response post-CPB may be attenuated by pre-opera-
tive statin therapy. The findings of this review and the strength
of the conclusions are limited by several factors related to the
current state of evidence; the total number of studies is limited,
the trial size is generally small, and the methodological quality
of trials is generally not high. Although key investigators in this
field who were contacted did not reveal any unpublished data,
an additional limitation to this systematic review is that we did
not statistically evaluate publication bias; the number of iden-
tified trials was small and the utility of such tests to assess the
possibility of bias in this situation is extremely limited.
A meta-analysis of similar, well-conducted, RCTs is consid-
ered one of the highest levels of evidence but the primary trials
all have to be conducted with high methodological rigor for the
meta-analysis to be definitive. This is not the case for the evi-
dence summarized in this review. In addition, controversy also
arises around the interpretation of summarized results when
the results of discordant studies are pooled in meta-analysis;
this systematic review identified studies that are diverse partic-
ularly in regards to the type and dose of statin used and the
duration of pre-operative therapy. There is currently no data
available regarding type, dose, or duration of statin therapy in
regards to modification of either post-operative clinical out-
comes or the inflammatory response. The current body of evi-
dence reviewed does not provide adequate data to examine
Figure 6
Forest plot of comparison for prophylactic statin therapy versus standard care/placebo: Inflammatory markers, outcome: TNF-α Forest plot of comparison for prophylactic statin therapy versus standard care/placebo: Inflammatory markers, outcome: TNF-α.  Total refers to no. of 
patients per trial. CI = confidence interval; SD = standard deviation.Critical Care    Vol 13 No 5    Morgan et al.
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directly treatment regimen to make any final conclusions on
this topic. Lastly, small meta-analyses like those published
here need to be regarded with caution even in the presence of
statistically significant results.
Given that the existing RCTs relating to the current topic have
important scientific and methodological limitations, including
smaller sized samples, the importance of this systematic
review lies in its identification of the gaps existing in the litera-
ture. In addition, the exploratory nature of the meta-analyses
undertaken in this review provides a plausible estimate of
effect that can be tested in subsequent studies.
Conclusions
Although the RCT evidence may suggest a reduction in post-
CPB inflammation by statin therapy, the evidence is not defin-
itive due to significant limitations. Several of the trials were not
methodologically rigorous and statin intervention was highly
variable in this small number of studies. This systematic review
demonstrates that there is a significant gap that exists in the
current literature in regards to the potential anti-inflammatory
effect of statin therapy prior to CPB. Further well-designed
RCTs would help fill this gap and guide a rational development
and use of interventions aimed at improving clinical outcomes
post-CPB. There are two ongoing RCTs with large target sam-
ple sizes (over 600 patients in total), which will hopefully con-
tribute some further evidence to this topic.
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